CN Patent
CN120058686A — 一种取代四氢呋喃化合物的可药用盐、其结晶形式及用途
Assigned to Shandong Shengdi Pharmaceutical Co ltd · Expires 2025-05-30 · 1y expired
What this patent protects
本公开涉及一种取代四氢呋喃化合物的可药用盐、其结晶形式及用途。具体而言,本公开提供(2R,3S,4S,5R)‑3‑(3,4‑二氟‑2‑甲氧基苯基)‑N‑(2‑((Z)‑(N’‑甲氧基甲脒基)吡啶‑4‑基)‑4,5‑二甲基‑5‑(三氟甲基)四氢呋喃‑2‑甲酰胺的可药用盐、晶型及其制备方法,相应盐具有良好的稳定性,可更好地用于临床治疗。
USPTO Abstract
本公开涉及一种取代四氢呋喃化合物的可药用盐、其结晶形式及用途。具体而言,本公开提供(2R,3S,4S,5R)‑3‑(3,4‑二氟‑2‑甲氧基苯基)‑N‑(2‑((Z)‑(N’‑甲氧基甲脒基)吡啶‑4‑基)‑4,5‑二甲基‑5‑(三氟甲基)四氢呋喃‑2‑甲酰胺的可药用盐、晶型及其制备方法,相应盐具有良好的稳定性,可更好地用于临床治疗。
Drugs covered by this patent
- Journavx (SUZETRIGINE) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.